Global Multiple Sclerosis Drugs Market 2024 , Forecast To 2033
7 Mar, 2024
The multiple sclerosis drugs market has experienced strong growth recently, with its size increasing from $29.66 billion in 2023 to $31.5 billion in 2024, marking a compound annual growth rate (CAGR) of 6.2%. This growth can be attributed to factors such as the rising prevalence of multiple sclerosis and growing investments from pharmaceuticals. Looking ahead, the market is expected to see continued growth, reaching $47.97 billion in 2028 at a CAGR of 11.1%. Factors contributing to this growth may include increasing availability of clinical trials and expanding geographical reach. Major trends in this period could include innovation in drug formulations and patient-centric care.
Global Multiple Sclerosis Drugs Market Key Driver
Government and non-government support are aiding the growth of the multiple sclerosis drugs market (8). With investments like the $10 million towards the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo), initiatives supported by various organizations are boosting research and innovations in MS treatment, contributing to market growth.
Get A Free Sample Of The Global Multiple Sclerosis Drugs Market ReportGlobal Multiple Sclerosis Drugs Market Segments
The multiple sclerosis drugs market covered in this report is segmented –
1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Other Drug Classes
2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores
3) By Route Of Administration: Oral Drugs, Parenteral Drugs
By Geography: The countries covered in the multiple sclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the global multiple sclerosis drug market in 2023. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Major Multiple Sclerosis Drugs Industry Players
Biogen Inc.; Novartis International AG; F. Hoffmann-La Roche Ltd.; Bayer HealthCare LLC; Pfizer Inc.; Merck & Co. Inc.; Sanofi S.A.; Teva Pharmaceutical Industries Ltd.; GlaxoSmithKline plc; Acorda Therapeutics Inc.; Actelion Pharmaceuticals Ltd; EMD Serono Inc.; AbbVie Inc.; Bayer Schering Pharma AG; CinnoVex; Rebif; Bristol-Myers Squibb Company; Johnson & Johnson; Mallinckrodt Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation; Mylan N.V.; Opexa Therapeutics Inc.; Receptos Inc.; Synthon Pharmaceuticals Inc.; TG Therapeutics Inc.; Alexion Pharmaceuticals Inc.; Alkermes plc; Amgen Inc.; Apitope Technology (Bristol) Ltd.; Atara Biotherapeutics Inc.; Celgene Corporation; Genzyme Corporation
Get The Full Global Multiple Sclerosis Drugs Market Report
Multiple Sclerosis Drugs Market Overview
Multi sclerosis drug refers to medications that are designed to stop the progression of disability and disease relapses. These medications are referred to as "disease-modifying treatments." These drugs target a protein on the surface of immune cells and reduce the number of white blood cells to help prevent MS relapses. The white blood cells' propensity for nerve injury may be reduced by this impact.